Literature DB >> 6597407

[Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin].

M Marty, G Ganem, J Fischer, G Flandrin, R Berger, G Schaison, L Degos, M Boiron.   

Abstract

A retrospective study of 119 patients with acute promyelocytic leukemia (APL) treated with similar DNR containing regimens in reported. Antecedent of radiation exposure or cancer was found in 10 patients. At presentation hyperleucocytosis was rare (13/119 greater than 30 000/microliter); variant form was identified in 5 cases. Organomegaly was uncommon and severe metabolic abnormality was never noted at presentation. DIC was observed in 75% of pts; t (15;17) was confirmed in 25/30 pts. Complete remission (CR) rates have increased from 43% to 76% on account of improvement of supportive therapy with adequate DIC management. Addition of ARA C did not improve CR rates (72%). Surprisingly duration of CR seems related to maintenance therapy as 11/26 pts receiving 6 MP-MTX maintenance regimen were long-term survivors as compared to 1/34 comparable pts receiving cyclic monthly courses of chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6597407

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol


  12 in total

Review 1.  Is cytarabine required in the treatment of acute promyelocytic leukemia?

Authors:  Lionel Adès; Pierre Fenaux
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

2.  High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA.

Authors:  M Aljurf; F Al Qurashi; F Al Mohareb; E Sahovic; F Al Sharif; H Al Zahrani; A Al Shanqeeti; T Owaidah; A Iqbal; S Z A Zaidi; Z A Nurgat; M Sanz; N Chaudhri
Journal:  Med Oncol       Date:  2009-08-08       Impact factor: 3.064

Review 3.  Management of acute promyelocytic leukemia.

Authors:  Martin S Tallman; Chadi Nabhan
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

4.  All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129.

Authors:  Dan Douer; Lynette N Zickl; Charles A Schiffer; Fredrick R Appelbaum; James H Feusner; Lois Shepherd; Cheryl L Willman; Clara D Bloomfield; Elisabeth Paietta; Robert E Gallagher; Jae H Park; Jacob M Rowe; Peter H Wiernik; Martin S Tallman
Journal:  Leuk Res       Date:  2013-03-23       Impact factor: 3.156

5.  Induction of acute lymphocytic leukemia differentiation by maintenance therapy.

Authors:  T L Lin; M S Vala; J P Barber; J E Karp; B D Smith; W Matsui; R J Jones
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

6.  Newly diagnosed acute promyelocytic leukemia.

Authors:  Giuseppe Avvisati
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-20       Impact factor: 2.576

7.  Treatment of acute promyelocytic leukemia with high white cell blood counts.

Authors:  C Kelaidi; L Adès; P Fenaux
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-09-08       Impact factor: 2.576

Review 8.  Acute promyelocytic leukemia: where did we start, where are we now, and the future.

Authors:  C C Coombs; M Tavakkoli; M S Tallman
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

9.  Distribution of Different PML/RARα bcr Isoforms in Indian Acute Promyelocytic Leukemia (APL) Patients and Clinicohematological Correlation.

Authors:  Tathagata Chatterjee; Srishti Gupta; Sanjeevan Sharma; Prosenjit Ganguli
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-01-02       Impact factor: 2.576

Review 10.  Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.

Authors:  Derek McCulloch; Christina Brown; Harry Iland
Journal:  Onco Targets Ther       Date:  2017-03-14       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.